Princeton Global Asset Management LLC Acquires 291 Shares of Gilead Sciences, Inc. $GILD

Princeton Global Asset Management LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 58.2% during the second quarter, Holdings Channel.com reports. The firm owned 791 shares of the biopharmaceutical company’s stock after acquiring an additional 291 shares during the quarter. Princeton Global Asset Management LLC’s holdings in Gilead Sciences were worth $88,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management grew its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $27,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the first quarter worth about $29,000. Finally, Colonial Trust Advisors boosted its position in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the sale, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,500 shares of company stock worth $8,281,540. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $123.11 on Tuesday. The company has a market cap of $152.76 billion, a P/E ratio of 24.52, a P/E/G ratio of 0.84 and a beta of 0.34. The firm’s fifty day moving average price is $115.27 and its two-hundred day moving average price is $110.62. Gilead Sciences, Inc. has a one year low of $85.60 and a one year high of $124.11. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 EPS. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Analyst Ratings Changes

Several research firms have weighed in on GILD. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $108.00 to $127.00 in a research note on Friday, August 8th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $121.14.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.